/
Hematology
Amyloidosis
47
Pipeline Programs↗
88
Active Trials↗
33
Companies Involved↗
Amyloidosis is a moderately active landscape with 47 programs across 33 companies. The most active players are Qilu Pharmaceutical Co., Ltd., GSK, Novo Nordisk. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical9
Phase 17
Phase 218
Phase 313
Approved
No programs
Analysis
Modality Breakdown
71%
Small molecule
27 of 38 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 38 classified programs, each share of the total. Modality classified for 87% of 47 pipeline programs.
Analysis
Trial Status
222
clinical trials
Completed99 · 45%
Recruiting54 · 24%
Terminated21 · 9%
Active, not recruiting16 · 7%
Not yet recruiting14 · 6%
Withdrawn7 · 3%
Other11 · 5%
Clinical Trials
Trial Activity
222 trials
Echocardiographic Characterization of Cardiac Amyloidosis: an Observational Study
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT05760287·255 enrolled
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)